Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster

Rhea-AI Summary

Caring Brands (Nasdaq:CABR) and SanPellegrino Cosmetics signed a revised, multi-territory licensing deal for Photocil and Hair Enzyme Booster, effective May 21, 2026.

The five-year agreement, with automatic annual renewal, extends SCPL’s rights from India into LATAM, Russia, Australia and New Zealand, leveraging existing Asian partnerships and clinical validation in dermatology and hair growth.

Positive

• Five-year initial licensing term with automatic annual renewal for SCPL
• Expanded territory coverage to India, LATAM, Russia, Australia and New Zealand
• Products already show commercial performance and clinical acceptance in India and Asia
• Hair Enzyme Booster licensed to major pharma and hair science brands across Asia
• Existing sublicense network supports broader international commercialization footprint

Negative

• None.

News Market Reaction – CABR

+17.12%

6 alerts

+17.12% Session close to close

+7.4% Peak in 16 min

$11.81M Market Cap

1.0x Rel. Volume

In the Jun 1 session, CABR gained 17.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.4% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +17.1% in the session following this news. A strong positive reaction aligns with C...

Analysis

The stock surged +17.1% in the session following this news. A strong positive reaction aligns with Caring Brands’ history of favorable responses to strategic deals, such as prior licensing and IP wins that saw gains of 15.44% and 24%. The expanded five-year multi-territory agreement for Photocil and Hair Enzyme Booster reinforces an asset-light, licensing-led model. Investors reviewing sustainability would likely weigh execution risk, regulatory progress in new markets, and the company’s recent financial filings highlighting losses and going-concern uncertainty.

Key Figures

Agreement term: 5 years Effective date: May 21, 2026 Commercial history: Over 3 years +2 more

5 metrics

Agreement term 5 years Revised multi-territory licensing agreement initial term

Effective date May 21, 2026 Effective date of revised licensing agreement

Commercial history Over 3 years Prior commercialization of Photocil and Hair Enzyme Booster in India

Target enzyme SULT1A1 Enzyme levels increased by Hair Enzyme Booster in clinical studies

Territories added LATAM, Russia, Australia, New Zealand Expanded coverage beyond India for licensed products

Historical Context

2 past events · Latest: Feb 03 (Positive)

Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 03	IP strengthening	Positive	+15.4%	Two new U.S. patents expanding Hair Enzyme Booster sulfotransferase IP.
Jan 05	Product licensing	Positive	+24.0%	Exclusive global license to manufacture and market Emesyl nausea product.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive strategic news (IP, licensing) previously aligned with strong positive price reactions.

Recent Company History

Over the last few months, Caring Brands reported several business-building steps. On Jan 5, 2026, it secured an exclusive global license for Emesyl, an OTC nausea product, which coincided with a 24% gain. On Feb 3, 2026, two new U.S. patents strengthened IP around Hair Enzyme Booster, followed by a 15.44% rise. Today’s expanded multi-territory licensing for Photocil and Hair Enzyme Booster extends that commercialization and IP-leveraging trajectory across additional global markets.

Key Terms

vitiligo, psoriasis, atopic dermatitis, sult1a1, +4 more

8 terms

vitiligo medical

"option for dermatologists treating vitiligo, psoriasis, and atopic dermatitis."

An autoimmune skin condition in which the body’s immune system destroys pigment-producing cells, causing irregular white patches on the skin; think of it like paint fading in isolated areas. It matters to investors because the condition creates demand for medical treatments, topical products and cosmetic coverage, so advances in therapies, clinical trial results or regulatory approvals can alter potential market size and a company’s future revenue prospects.

psoriasis medical

"option for dermatologists treating vitiligo, psoriasis, and atopic dermatitis."

Psoriasis is a chronic skin condition where the body's defenses cause skin cells to build up rapidly, producing red, scaly, and often itchy patches. It matters to investors because it creates a steady market for long-term treatments, devices and services—similar to a recurring customer need—affecting drug development, clinical trial pipelines, pricing, and healthcare spending across pharmaceuticals and medical providers.

atopic dermatitis medical

"option for dermatologists treating vitiligo, psoriasis, and atopic dermatitis."

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

sult1a1 medical

"shown in clinical studies to increase levels of the SULT1A1 (Sulfotransferase) enzyme,"

SULT1A1 is a human gene that makes an enzyme responsible for adding a small chemical tag (a sulfate) to hormones, drugs and other foreign compounds, which helps the body change, move or remove them. For investors, variations in this gene can alter how patients process medications—affecting a drug’s effectiveness, side effects, dosing needs or market potential—so it matters for drug development, safety testing and personalized medicine decisions.

sulfotransferase medical

"increase levels of the SULT1A1 (Sulfotransferase) enzyme, which is essential"

An enzyme that attaches a small sulfate “tag” onto drugs, hormones and other molecules, changing how the body recognizes, moves or breaks them down. For investors, sulfotransferases matter because this chemical tagging can speed or slow drug clearance, alter effectiveness or create safety concerns, and therefore influence clinical outcomes, regulatory decisions and a drug’s commercial value—like a postage stamp that determines where a package ends up.

minoxidil medical

"essential for converting Minoxidil into its active form, Minoxidil Sulfate,"

A topical medicine used to treat hair loss that helps stimulate shrinking hair follicles to produce thicker, longer hairs; it is also available as an oral drug for severe high blood pressure. Investors care because minoxidil’s regulatory approval status, over‑the‑counter availability, patent situation and clinical data directly affect sales, market size and competitive dynamics — think of it as a widely used product whose distribution and label changes can quickly change revenue for makers and sellers.

minoxidil sulfate medical

"converting Minoxidil into its active form, Minoxidil Sulfate, thereby promoting"

Minoxidil sulfate is the chemically active form of minoxidil, the ingredient that stimulates hair follicles to grow hair; in the body or in topical products minoxidil is converted into this sulfate form which does the work. Investors care because its effectiveness, ease of manufacturing, patent protection, and regulatory status directly affect product performance, market size, and a company’s ability to sell hair-growth treatments—think of it as the key that actually turns the lock on hair regrowth.

topical formulation medical

"a clinically validated, patented topical formulation developed to support the treatment"

A topical formulation is a medicine or product made to be applied directly to the skin, eyes, or other external surfaces—think creams, gels, ointments or sprays—so the active ingredient works where it is applied. For investors, it matters because how a drug is formulated affects its safety, ease of manufacture, patent protection, regulatory path and market appeal; a better topical can be cheaper to produce, faster to approve, and easier to sell, much like packaging that makes a product easier to use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Five-Year Agreement Extends Commercial Reach Across India, LATAM, Russia, Australia and New Zealand

Fort Pierce, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR), a consumer brands company specializing in skin care and hair growth, and SanPellegrino Cosmetics Private Limited (“SCPL”), a New Delhi-based specialty pharma and dermatology licensing company, today announced the execution of a revised multi-territory licensing agreement covering Photocil and Hair Enzyme Booster.

The revised agreement, effective May 21, 2026, builds on over three years of successful commercialization and expands the scope and term of the parties’ existing commercial relationship across key global markets. Both Photocil and Hair Enzyme Booster are currently manufactured in India.

Since their launch in India, both Photocil and Hair Enzyme Booster have demonstrated good commercial performance and clinical acceptance across the dermatology and hair science communities. Photocil — commercialized as Photofirst by Eris Lifesciences, (“Eris”) one of India’s leading specialty pharma companies — has established itself as a clinically differentiated option for dermatologists treating vitiligo, psoriasis, and atopic dermatitis. The Hair Enzyme Booster has begun to achieve significant traction across India and Asia, having been licensed by SCPL to some of the world’s largest hair science and pharmaceutical brands including Dr. Reddy’s Laboratories, Cipla, Dabur, Eris Lifesciences, and Glenmark Pharmaceuticals, which we believe underscores the technology’s broad global commercial validation.

The revised agreement grants SCPL an extended five-year initial term with automatic annual renewal. The expanded territory set now covers India (existing), LATAM (Mexico, Brazil, Colombia, Ecuador, Peru, Dominican Republic, Trinidad and Tobago), Russia, and Australia and New Zealand. SCPL’s existing sublicense partnerships include Eris in India and Glenmark Pharmaceuticals across Asia and the Middle East, where Hair Enzyme Booster has been registered or is in active regulatory review across multiple markets including Malaysia, Vietnam, Cambodia, UAE, Kuwait, and Saudi Arabia — reflecting a well-established regional commercialization footprint that underpins the expanded agreement.

Photocil is a clinically validated, patented topical formulation developed to support the treatment of vitiligo, psoriasis, and atopic dermatitis. Hair Enzyme Booster is a first-of-its-kind, patented topical formulation shown in clinical studies to increase levels of the SULT1A1 (Sulfotransferase) enzyme, which is essential for converting Minoxidil into its active form, Minoxidil Sulfate, thereby promoting hair growth.

Dr. Glynn Wilson, CEO of Caring Brands, commented, “This expanded agreement reflects our confidence in SCPL’s commercial execution and our shared vision for bringing these clinically validated technologies to patients across high-growth international markets in order to improve our revenue stream.”

Arjun Khurana, Founder and Director of SanPellegrino Cosmetics Private Limited, said, “Over the past three years, we have built a strong foundation for both Photocil and Hair Enzyme Booster across India and Asia, supported by a robust network of leading pharmaceutical partners and a growing body of real-world clinical evidence. This expanded agreement positions us to bring these differentiated dermatology technologies to a significantly broader patient population across LATAM, Russia, Australia, and New Zealand.”

About Caring Brands

Caring Brands Inc. has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. The Company intends to launch a total of five products over the next two years in addition to in-licensing additional products. Management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.

About SanPellegrino Cosmetics Private Limited

SanPellegrino Cosmetics Private Limited (SCPL) is a New Delhi-based specialty pharma and dermatology licensing company operating across India, LATAM, MENA, ANZ, SEA, CIS, and Korea. SCPL sub-licenses clinically proven technologies in dermatology and hair science through established partnerships with leading regional pharmaceutical companies including Eris Lifesciences and Glenmark Pharmaceuticals. For more information, visit www.spcindia.net.

Contact

Caring Brands

Brian S John
Chief Investment Officer
(561) 896-7616

SanPellegrino Cosmetics Private Limited

Arjun Khurana,
Founder & Director

arjunkhurana@spcindia.net
www.spcindia.net
www.photociltherapy.com

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the federal securities laws regarding Caring Brands, Inc. (“Company”), including, without limitation, statements regarding the anticipated timing of studies and the expected results, benefits and potential outcomes thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative of such terms thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these identifying words.

These forward-looking statements are based on each of the Company’s current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond our control. Actual results, performance or achievements, including the timing of events, may differ materially from those expressed or implied by the forward-looking statements as a result of various risks and uncertainties, including those described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other subsequent filings with the SEC. Copies of these filings are available on the SEC’s website at www.sec.gov. Investors are cautioned that forward-looking statements are not guarantees of future performance, and are cautioned not to place undue reliance on any such forward-looking statements. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update, revise or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances occurring after the date such statements were made, except as required by applicable law.

FAQ

What is the new licensing agreement between Caring Brands (NASDAQ:CABR) and SanPellegrino Cosmetics?

The companies signed a revised multi-territory licensing agreement for Photocil and Hair Enzyme Booster. According to Caring Brands, it extends their existing relationship and broadens commercial rights for these topical dermatology and hair growth formulations across several key international markets.

Which territories are covered in the expanded Caring Brands (CABR) licensing deal announced June 1, 2026?

The revised agreement covers India, LATAM, Russia, Australia and New Zealand. According to Caring Brands, LATAM includes Mexico, Brazil, Colombia, Ecuador, Peru, Dominican Republic, and Trinidad and Tobago, significantly increasing the geographic reach for Photocil and Hair Enzyme Booster.

What is the duration of the Caring Brands and SanPellegrino Cosmetics licensing agreement for Photocil and Hair Enzyme Booster?

The revised licensing agreement has a five-year initial term with automatic annual renewal. According to Caring Brands, this longer structure builds on more than three years of commercialization experience and supports sustained international rollout of both patented topical products.

How are Photocil and Hair Enzyme Booster positioned clinically in the Caring Brands (CABR) portfolio?

Photocil and Hair Enzyme Booster are described as clinically validated, patented topical formulations. According to Caring Brands, Photocil supports treatment of vitiligo, psoriasis and atopic dermatitis, while Hair Enzyme Booster increases SULT1A1 enzyme levels to help convert Minoxidil into its active hair growth form.

Which pharmaceutical partners are involved with Hair Enzyme Booster under the Caring Brands licensing strategy?

Hair Enzyme Booster has been licensed by SCPL to several major brands, including Dr. Reddy’s, Cipla, Dabur, Eris and Glenmark. According to Caring Brands, these partnerships and regional registrations support a broad commercialization footprint across India, Asia and the Middle East.

How might the expanded CABR licensing agreement impact Caring Brands’ international revenue potential?

Management suggests the agreement supports efforts to improve the company’s revenue stream. According to Caring Brands, expanded territorial rights and SCPL’s established partner network aim to bring Photocil and Hair Enzyme Booster to more patients across high-growth international dermatology and hair growth markets.